Premium
Comparative analysis of marketed factor VIII products: reply
Author(s) -
Reipert B. M.,
Anzengruber J.,
Scheiflinger F.
Publication year - 2019
Publication title -
journal of thrombosis and haemostasis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.947
H-Index - 178
eISSN - 1538-7836
pISSN - 1538-7933
DOI - 10.1111/jth.14349
Subject(s) - immunogenicity , clarity , transparency (behavior) , medicine , antibody , immunology , biology , computer science , biochemistry , computer security
Development of factor VIII (FVIII) inhibitors following replacement therapy with FVIII is one of the major challenges faced when treating patients with hemophilia A. Inhibitors develop in 20-32% of previously untreated patients with severe and in 3-13% with moderate or mild hemophilia A (1,2). The cause of the immunogenicity is not well understood. There is evidence that both genetic and non-genetic factors influence patients' susceptibility to develop these antibodies (3,4). This article is protected by copyright. All rights reserved.